Nurse Corner

Resources for You

For US healthcare professionals.

Indications

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:

  • Unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:
    • In the metastatic setting, or
    • In the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy
  • Unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy
  • Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen

Indications

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:

  • Unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:
    • In the metastatic setting, or
    • In the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy
  • Unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy
  • Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen

For metastatic breast cancer

Nurse Infusion Guide

Understand how to dose, prepare, administer, and infuse ENHERTU.

Pocket Dosing Guide

Quick reference on ENHERTU dosage and how to adjust based on adverse reactions.

For HER2+ metastatic breast cancer

HER2+ mBC HCP Resource Guide

Review the DESTINY-Breast03 efficacy and safety data, how to administer, and recommendations for adverse reaction management.

For HER2-low metastatic breast cancer

HER2-low mBC Efficacy and Safety Guide

See the ENHERTU data from DESTINY-Breast04.

HER2-low mBC HCP Resource Guide

Review the DESTINY-Breast04 efficacy and safety data, how to administer, and recommendations for adverse reaction management.

HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; mBC, metastatic breast cancer; NSCLC, non-small cell lung cancer.